Get all premium features to the best stock analysis tool

Finranks

Finranks

Company

  • About us

Contact us

  • [email protected]

Follow us

  • Instagram
  • Telegram
  • LinkedIn

All rights reserved.

Privacy PolicyTerms of Conditions
  • Home
  • Markets
  • Screener
  • News
  • About
  1. Home
  3. XGN

(XGN)

NGM – Real Time Price. Currency in USD

2.68

-0.11 (-3.94%)

At close: Mar 27, 2026, 4:00 PM EDT

2.68

0.00 (0.00%)

After-hours: Mar 27, 2026, 4:10 PM EDT

  • Summary
  • News
  • Chart
  • Financial
  • Dividends
  • Forecast
  • Ownership
  • Profile
Exagen Inc. (XGN) Q4 2025 Earnings Call Transcript
10.03.2026

Exagen Inc. (XGN) Q4 2025 Earnings Call Transcript

Exagen Inc. (XGN) Q4 2025 Earnings Call Transcript

Exagen Inc. (XGN) Reports Q4 Loss, Beats Revenue Estimates
10.03.2026

Exagen Inc. (XGN) Reports Q4 Loss, Beats Revenue Estimates

Exagen Inc. (XGN) came out with a quarterly loss of $0.2 per share in line with the Zacks Consensus Estimate. This compares to a loss of $0.2 per share a year ago.

Exagen Inc. Reports Strong Fourth Quarter and Full-Year 2025 Results
10.03.2026

Exagen Inc. Reports Strong Fourth Quarter and Full-Year 2025 Results

Record full-year total revenue and AVISE® CTD average selling price New biomarkers and sales force expansion drove over 11% full-year test volume growth CARLSBAD, Calif., March 10, 2026 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing, today reported financial results for the fourth quarter and full year ended December 31, 2025, and recent business highlights.

Exagen Inc. to Participate in Upcoming Investor Conferences
03.03.2026

Exagen Inc. to Participate in Upcoming Investor Conferences

CARLSBAD, Calif., March 03, 2026 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing, today announced that management will participate in the following investor conferences: KeyBank Capital Markets Healthcare Forum - Virtual Date: March 17, 2026 Participation: Investor meetings and fireside chat at 3:00 p.m.

Exagen Inc. to Announce Fourth Quarter and Full Year 2025 Financial Results on March 10, 2026
24.02.2026

Exagen Inc. to Announce Fourth Quarter and Full Year 2025 Financial Results on March 10, 2026

CARLSBAD, Calif., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of innovative autoimmune testing, will release financial results for the quarter ended December 31, 2025, before the market opens on Tuesday, March 10, 2026. John Aballi, President and Chief Executive Officer, and Jeff Black, Chief Financial Officer, will host a conference call to review the company's results at 8:30 a.m. ET (5:30 a.m. PT).

Exagen Inc. Announces Select Preliminary 2025 Financial Results
11.01.2026

Exagen Inc. Announces Select Preliminary 2025 Financial Results

CARLSBAD, Calif., Jan. 11, 2026 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing, today announced select preliminary unaudited financial results for the fourth quarter and year ended December 31, 2025, in line with prior financial guidance.

Exagen Inc. to Participate in Fourth Quarter Investor Conferences
11.11.2025

Exagen Inc. to Participate in Fourth Quarter Investor Conferences

CARLSBAD, Calif., Nov. 11, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing, today announced that management will participate in the following upcoming investor conferences:

Videos

No Data

There is no data to display